Field Of Vision
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Nov 21, 2012; 18(43): 6183-6188
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6183
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 The outcome of the five landmark trials for telaprevir-based triple therapy in hepatitis C virus genotype 1 patients. Sustained virologic response rates are compared between groups. PROVE 1, PROVE 2 and ADVANCE trials were conducted in treatment-naïve patients. PROVE 3 and REALIZE trials were conducted in treatment-experienced patients. T: Telaprevir; P: Peg-IFN; R: Ribavirin; The numbers (8, 12, 24 or 48): Week of treatment; SVR: Sustained virologic response.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 The outcome of the three landmark trials for boceprevir-based triple therapy in hepatitis C virus genotype 1 patients. Sustained virologic response rates are compared between groups. The SPRINT-1 and SPRINT-2 trials were conducted in treatment-naïve patients. The RESPOND-2 trial was conducted in treatment-experienced patients. B: Boceprevir; P: Peg-interferon; R: Ribavirin; The numbers (4, 24, 28 or 48): Week of treatment; SVR: Sustained virologic response; RGT: Response-guided telaprevir combination treatment.